Merck Drug Patent Portfolio
Merck owns 4 orange book drugs protected by 31 US patents Given below is the list of Merck's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8258132 | Pharmaceutical composition of a tachykinin receptor antagonist | 26 Sep, 2027 | Active |
| US5994329 | Method for inhibiting bone resorption | 17 Jan, 2019 | Expired |
| US6015801 | Method for inhibiting bone resorption | 17 Jan, 2019 | Expired |
| US6225294 | Method for inhibiting bone resorption | 17 Jan, 2019 | Expired |
| US5994329 | Method for inhibiting bone resorption | 17 Jul, 2018 | Expired |
| US6015801 | Method for inhibiting bone resorption | 17 Jul, 2018 | Expired |
| US6225294 | Method for inhibiting bone resorption | 17 Jul, 2018 | Expired |
| US6096742 | Polymorphic form of a tachykinin receptor antagonist | 01 Jul, 2018 | Expired |
| US6063811 | Compositions for a once day treatment of cyclooxygenase-2 mediated diseases | 06 Nov, 2017 | Expired |
| US5952300 | Antifungal compositions | 28 Sep, 2017 | Expired |
| US6136783 | Antifungal compositions | 28 Sep, 2017 | Expired |
| US6063811 | Compositions for a once day treatment of cyclooxygenase-2 mediated diseases | 06 May, 2017 | Expired |
| US5952300 | Antifungal compositions | 28 Mar, 2017 | Expired |
| US6136783 | Antifungal compositions | 28 Mar, 2017 | Expired |
| US5691374 | Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors | 18 Nov, 2015 | Expired |
| US5514650 | Aza cyclohexapeptide compounds | 26 Jul, 2015 | Expired |
| US5691374 | Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors | 18 May, 2015 | Expired |
| US5719147 | Morpholine and thiomorpholine tachykinin receptor antagonists | 17 Apr, 2015 | Expired |
| US5514650 | Aza cyclohexapeptide compounds | 26 Jan, 2015 | Expired |
| US5462932 | Oral liquid alendronate formulations | 17 Nov, 2014 | Expired |
| US5462932 | Oral liquid alendronate formulations | 17 May, 2014 | Expired |
| US5474995 | Phenyl heterocycles as cox-2 inhibitors | 24 Dec, 2013 | Expired |
| US6239173 | 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor | 24 Dec, 2013 | Expired |
| US5378804 | Aza cyclohexapeptide compounds | 16 Sep, 2013 | Expired |
| US5792746 | Aza cyclohexapeptide compounds | 16 Sep, 2013 | Expired |
| US5538982 | Medical use for tachykinin antagonists | 23 Jul, 2013 | Expired |
| US5474995 | Phenyl heterocycles as cox-2 inhibitors | 24 Jun, 2013 | Expired |
| US6239173 | 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor | 24 Jun, 2013 | Expired |
| US5378804 | Aza cyclohexapeptide compounds | 16 Mar, 2013 | Expired |
| US5792746 | Aza cyclohexapeptide compounds | 16 Mar, 2013 | Expired |
| US7214692 | Medical use for tachykinin antagonists | 18 Sep, 2012 | Expired |
Latest Legal Activities on Merck's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Merck.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 08 Feb, 2024 | US8258132 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 18 Feb, 2020 | US8258132 |
|
Expire Patent
Critical
| 05 Jun, 2015 | US7214692 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 04 Sep, 2012 | US8258132 |
|
Recordation of Patent Grant Mailed
Critical
| 04 Sep, 2012 | US8258132 |
|
Issue Notification Mailed
Critical
| 15 Aug, 2012 | US8258132 |
|
Application Is Considered Ready for Issue
Critical
| 01 Aug, 2012 | US8258132 |
| Dispatch to FDC | 01 Aug, 2012 | US8258132 |
|
Issue Fee Payment Received
Critical
| 30 Jul, 2012 | US8258132 |
|
Issue Fee Payment Verified
Critical
| 30 Jul, 2012 | US8258132 |
| Printer Rush- No mailing | 14 Jun, 2012 | US8258132 |
| Mail Miscellaneous Communication to Applicant | 14 Jun, 2012 | US8258132 |
| Miscellaneous Communication to Applicant - No Action Count | 12 Jun, 2012 | US8258132 |
|
Pubs Case Remand to TC
Critical
| 07 Jun, 2012 | US8258132 |
|
Mail Notice of Allowance
Critical
| 03 May, 2012 | US8258132 |
Merck's Drug Patent Litigations
Merck's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jul 26, 2005, against patent number US7214692. The petitioner , challenged the validity of this patent, with Russell Michael Hagan et al as the respondent. Click below to track the latest information on how companies are challenging Merck's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7214692 | July, 2005 |
Decision
(18 Jan, 2006)
| Russell Michael Hagan et al | |
Merck Drug Patents' Oppositions Filed in EPO
Merck drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 06, 2009, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP02796109A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP02796109A | Apr, 2009 | Hexal AG | Patent maintained as amended |
| EP02796109A | Apr, 2009 | Teva Pharmaceutical Industries Ltd. | Patent maintained as amended |
Merck's Family Patents
Merck Drug List
Given below is the complete list of Merck's drugs and the patents protecting them.
1. Cancidas
Cancidas is protected by 10 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5952300
(Pediatric)
| Antifungal compositions |
28 Sep, 2017
(7 years ago)
| Expired |
| US6136783
(Pediatric)
| Antifungal compositions |
28 Sep, 2017
(7 years ago)
| Expired |
| US5952300 | Antifungal compositions |
28 Mar, 2017
(8 years ago)
| Expired |
| US6136783 | Antifungal compositions |
28 Mar, 2017
(8 years ago)
| Expired |
| US5514650
(Pediatric)
| Aza cyclohexapeptide compounds |
26 Jul, 2015
(9 years ago)
| Expired |
| US5514650 | Aza cyclohexapeptide compounds |
26 Jan, 2015
(10 years ago)
| Expired |
| US5378804
(Pediatric)
| Aza cyclohexapeptide compounds |
16 Sep, 2013
(11 years ago)
| Expired |
| US5792746
(Pediatric)
| Aza cyclohexapeptide compounds |
16 Sep, 2013
(11 years ago)
| Expired |
| US5378804 | Aza cyclohexapeptide compounds |
16 Mar, 2013
(12 years ago)
| Expired |
| US5792746 | Aza cyclohexapeptide compounds |
16 Mar, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cancidas's drug page
2. Emend
Emend is protected by 5 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8258132 | Pharmaceutical composition of a tachykinin receptor antagonist |
26 Sep, 2027
(2 years from now)
| Active |
| US6096742 | Polymorphic form of a tachykinin receptor antagonist |
01 Jul, 2018
(6 years ago)
| Expired |
| US5719147 | Morpholine and thiomorpholine tachykinin receptor antagonists |
17 Apr, 2015
(10 years ago)
| Expired |
| US5538982 | Medical use for tachykinin antagonists |
23 Jul, 2013
(11 years ago)
| Expired |
| US7214692 | Medical use for tachykinin antagonists |
18 Sep, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Emend's drug page
3. Fosamax
Fosamax is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5994329
(Pediatric)
| Method for inhibiting bone resorption |
17 Jan, 2019
(6 years ago)
| Expired |
| US6015801
(Pediatric)
| Method for inhibiting bone resorption |
17 Jan, 2019
(6 years ago)
| Expired |
| US6225294
(Pediatric)
| Method for inhibiting bone resorption |
17 Jan, 2019
(6 years ago)
| Expired |
| US5994329 | Method for inhibiting bone resorption |
17 Jul, 2018
(6 years ago)
| Expired |
| US6015801 | Method for inhibiting bone resorption |
17 Jul, 2018
(6 years ago)
| Expired |
| US6225294 | Method for inhibiting bone resorption |
17 Jul, 2018
(6 years ago)
| Expired |
| US5462932
(Pediatric)
| Oral liquid alendronate formulations |
17 Nov, 2014
(10 years ago)
| Expired |
| US5462932 | Oral liquid alendronate formulations |
17 May, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fosamax's drug page
4. Vioxx
Vioxx is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6063811
(Pediatric)
| Compositions for a once day treatment of cyclooxygenase-2 mediated diseases |
06 Nov, 2017
(7 years ago)
| Expired |
| US6063811 | Compositions for a once day treatment of cyclooxygenase-2 mediated diseases |
06 May, 2017
(8 years ago)
| Expired |
| US5691374
(Pediatric)
| Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors |
18 Nov, 2015
(9 years ago)
| Expired |
| US5691374 | Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors |
18 May, 2015
(10 years ago)
| Expired |
| US5474995
(Pediatric)
| Phenyl heterocycles as cox-2 inhibitors |
24 Dec, 2013
(11 years ago)
| Expired |
| US6239173
(Pediatric)
| 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor |
24 Dec, 2013
(11 years ago)
| Expired |
| US5474995 | Phenyl heterocycles as cox-2 inhibitors |
24 Jun, 2013
(11 years ago)
| Expired |
| US6239173 | 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor |
24 Jun, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vioxx's drug page